AI drug‑discovery and research‑software financing accelerated as Insilico Medicine filed to raise HK$2.27 billion (about $292M) in a Hong Kong IPO to advance its clinical pipeline and generative AI capabilities, while Edison Scientific closed a $70M seed round to commercialize autonomous research software. Both moves underscore investor appetite for companies applying generative AI to automate lab work and accelerate R&D. The capital raises reflect divergent go‑to‑market models: Insilico is a developer of AI‑discovered drug candidates moving toward clinical assets, whereas Edison aims to sell research automation and software to labs. Market observers will watch whether larger public exits and deep seed rounds translate into faster preclinical pipelines or durable software revenue.